A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults
Completed
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
2005-03-01
The specific aim of this study is to document the pharmacokinetics of dopamine transporter
DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane as
the ligand. We hypothesize that CNS DAT occupancy of OROS MPH will be greater than that of
Metadate CD at 10 hours after administration.
A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults
Completed
Massachusetts General Hospital
Phase 3
2005-03-01
The specific aim of this study is to document the pharmacokinetics of dopamine transporter
DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane as
the ligand. We hypothesize that CNS DAT occupancy of OROS MPH will be greater than that of
Metadate CD at 10 hours after administration.
The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
Completed
UCB Pharma
Phase 4
2002-05-01
This study was designed to compare Concerta Extended Release tablets with Metadate CD
capsules in children with ADHD who were between 6 and 12 years old. The effects on ADHD
symptoms, and any side effects of treatment, were measured for 12 hours after dosing in a
simulated classroom. The treatments were blinded and the effects were compared with a
Placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
